Drugs / Triprorelin Acetate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05247268 | Mar 2022 → Mar 2027 expected | endometrial carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05316935 | Jul 2022 → Mar 2026 overdue | atypical endometrial hyperplasia, endometrium neoplasm, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triprorelin acetate | “Triprorelin acetate” NCT05316935 ↗ |
| Route | Intramuscular | “Intramuscular injection of 3.75mg was given 4 weeks apart” NCT05247268 ↗ |